Oxford Immunotec Global PLC

Oxford Immunotec Global — Merger or Acquisition (September 2018)

9 slides from Oxford Immunotec Global's merger presentation, Sep 25, 2018

  1. Slide 1: Oxford Immunotec

    299 S§8 Oxford 606 Immunotec

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. This includes statements about the Company's an

  3. Slide 3: Transaction Summary

    Transaction Summary Overview Other Elements Purchase Price Expected Close Quest Diagnostics to acquire the U.S. laboratory services business of Oxford Immunotec in an all-cash equity transaction + Includes the T-SPOT®.TB tuberculosis and the Accutix™ tick-borne disease testing services provided by O

  4. Slide 4: Deal Benefits

    Deal Benefits ¢ Significantly increases the reach and competitiveness of T-SPOT.7B in the U.S. market ¢ Dramatically simplified operations as a pure-play products company ¢ Materially improved top and bottom line profitability ¢ Markedly stronger balance sheet and financial flexibility Oxford 4 Immu

  5. Slide 5: Quest Diagnostics CEO quote on acquisition rationale

    “This acquisition will extend our capabilities in infectious disease diagnostics, consistent with our strategy to accelerate growth by broadening access to diagnostic innovation. It will build on our momentumin tuberculosis services by enabling us to bring greater choice to physicians who seek innov

  6. Slide 6: Broadening Market Access for T-SPOT.TB

    Broadening Market Access for T-SPOT.7B By leveraging Quest's reach and capabilities, U.S. market access to T-SPOT.7B will be immediately broadened: mw Enables unparalleled access to the large physician office market segment wm Helps remove barriers to adoption Gaining an additional voice in the mark

  7. Slide 7: Selected Financial Information

    Selected Financial Information Oxford immunotee TTM Preliminary ro omat.Ravenue Mi ocme | SEERRRTRTS TTM Gros: SQ rot _ Product —— Prine Service + Revenue guidance for full year 2018 to be updated following the closing of the transaction + Product ASP in the U.S. expected to be comparable to product

  8. Slide 8: Transaction timeline: signed, announced, expected close

    ¢« September 25, 2018: Signed Interest Purchase Agreement ¢ September 25, 2018: Announced Transaction ¢ Fourth Quarter of 2018: Expected Transaction Close! o Pro forma financials to be filed with the SEC within four days of transaction close 1 Subject to customary regulatory approvals end closing 1p

  9. Slide 9: Oxford Immunotec

    299 S§8 Oxford ©06 Immunotec

Oxford Immunotec Global — Merger or Acquisition (September 2018) on 6ix